// App-Quantinova.ai

625 : Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Researchers

Presenter

  • Peter Paschka

Principal Investigators

  • Xavier Thomas

  • Christian Recher

  • Sylvain Chantepie

  • Pau Montesinos Fernandez

  • Evelyn Acua-Cruz

  • Paresh Vyas

  • Karl-Anton Kreuzer

  • Michael Heuser

  • Klaus H. Metzeler

  • Michael Dennis

  • Bruno Quesnel

  • Hunault-Berger Mathilde

  • Mohamad Mohty

  • Arnaud Pigneux

  • Stephane De Botton

  • Daniela Weber

  • Konstanze Dohner

  • Gary Milkovich

  • John Reitan

  • Sarah C MacDonald

  • Deborah Casso

  • Michael Storm

  • Hua Liu

  • Stephanie M. Kapsalis

  • Eyal C. Attar

  • Thomas Winkler

  • Hartmut Dhner

Medical Centers

  • Universitatsklinikum Ulm, Ulm, Germany

  • Hospital Saint Antoine, Paris, France

  • Centre Hospitalo-Universitaire Lyon Sud, Lyon, France

  • Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse-Oncopôle,Toulouse,France

  • Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen, France

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • CIBEROBN, Instituto de SaludCarlos III, Madrid, Spain

  • University of Oxford, Oxford, United Kingdom

  • Uniklink Koln, Koln, Germany

  • Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Department of Hematology and Oncology, Univeristy of Munich, Munich, Germany

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Centre Hospitalier Regional Universitaire Lille, Lille, France

  • Pediatrie, Centre Hospitalier Universitaire d' Angers, Angers, France

  • Saint Antoine Hospital, paris, France

  • Centre Hospitalier Universitaire de Bordeaux, Bordeaux Cedex, France

  • Institut Gustave-Roussy, Villejuif, France

  • Klinik fuer Innere Medizin II, Uniklinikum Ulm, Ulm, Germany

  • RJM Group, LLC, Washington, DC

  • IQVIA, Kirkland, Quebec, Canada

  • IQVIA, Seattle, WA

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

Locations

  • Germany

  • France

  • Spain

  • United Kingdom

  • United States

  • Canada

Companies

  • Agios Pharmaceutical

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Isocitrate dehydrogenase 1

Drug/Treatment

  • AG120

  • C-001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02074839

  • NCT01252485

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved